ASCO 2021

Lung Cancer In-Depth

Complete Coverage

Percepta Genomic Sequencing Classifier May Improve Clinical Decision Making Regarding Lung Nodules

Researchers present data that demonstrate how the Percepta Genomic Sequencing Classifier can enhance care decisions regarding lung nodules.

A liquid biopsy or simple blood test can reliably and swiftly genotype 2 key genes associated with a

Prognostic Understanding Influences Patients’ Lung Cancer Care Decisions at the End of Life

Researchers assessed the associations between patients’ understanding of their prognosis and their end-of-life care decisions.

PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.

Multidisciplinary Response Program Improves Follow-up, Referrals for Suspicious Lung Nodules

Researchers present data on a program designed to increase completion rates among patients with suspicious lung nodules on screening CT.

Prediction Model Assesses Risk of Brain Metastasis in Patients With Non-Small Cell Lung Cancer

Researchers present their prediction model for assessing risk of brain metastases in patients with non-small cell lung cancer.

Studying how MGUS and myeloma clones change over time might yield new insights into myeloma’s molecu

Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment

Younger patients had a significant decrease in sleep time on days they received dexamethasone.

Even with early diagnosis, there appears to be a disproportionate toll from breast cancer in black w

Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases

Black patients were more likely than White patients to have distant metastases.

The FDA has accepted a New Drug Application (NDA) and granted Priority Review for venetoclax for tre

MRD Negativity Linked to Better Survival After Venetoclax-Azacitidine in Acute Myeloid Leukemia

Improvements were seen in event-free and overall survival.

The tool is still diagnostically useful in both cases, it just may require sex-specific guidelines for use.

Abemaciclib Plus Endocrine Therapy Deemed Beneficial in High-Risk Early Breast Cancer After Neoadjuvant Chemo

The combination improved invasive disease-free survival and distant relapse-free survival.

Pacritinib suppresses leukemic outgrowth from stroma-adherent cells in FLT3-ITD–driven AML.

Ivosidenib Plus Venetoclax, With or Without Azacitidine, Appears Effective in IDH1-Mutated Myeloid Malignancies

The 1-year overall survival rate was 71%.

The combination of vorinostat plus bortezomib is active in patients with multiple myeloma who are re

Combination Therapy Shows Promise in Patients With Ultra High-Risk Multiple Myeloma, PCL

Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.

Next post in ASCO 2021 Lung Cancer In-depth